Asset Details
Do you wish to reserve the book?
P317 Diagnostic yield of EUS-FNA in UGI submucosal lesions- experience from a non-tertiary centre in UK
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
P317 Diagnostic yield of EUS-FNA in UGI submucosal lesions- experience from a non-tertiary centre in UK
Do you wish to request the book?
P317 Diagnostic yield of EUS-FNA in UGI submucosal lesions- experience from a non-tertiary centre in UK
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
P317 Diagnostic yield of EUS-FNA in UGI submucosal lesions- experience from a non-tertiary centre in UK
2022
Overview
IntroductionEUS guided tissue acquisition is a well established investigation to confirm the histopathological diagnosis for submucosal lesions in upper gastrointestinal tract. The European Society of Gastrointestinal Endoscopy (ESGE) and Joint Advisory Group (JAG) suggests the frequency of obtaining a diagnostic tissue sample of at least 85% for EUS-FNA (1). The aim of this study was to determine the diagnostic adequacy and safety of EUS guided tissue acquisition in submucosal lesions.MethodsWe carried out a retrospective audit of all patients (identified from endoscopy and pathology database) who underwent EUS guided tissue acquisition between 1st October 2019 and 30th November 2021. Data collected include patient demographics, cross-sectional imaging, cytopathological diagnoses, treatment modality, complications and 30-day procedure related mortality. Final diagnoses were confirmed from EUS biopsy, surgical resection specimen or cross-sectional imaging (discussed in a MDT setting if histology negative).Results39 patients [mean age 66.7 years, 36.8% females] underwent 39 EUS-FNA procedures (18 and 21 patients had a cancer and benign diagnosis respectively).33 (85%) samples were deemed adequate for analysis by the cytopatholgist (5 diagnosed as lipoma on EUS appearance and 1 diagnosed as GIST on CT/EUS appearance under surgical follow up). Sensitivity, specificity, diagnostic accuracy, positive predictive value (PPV) and negative predictive value (NPV) were 94.8%, 100%, 85%, 100%, and 94.1% respectively. There was no procedure related complications or mortality.Histopathological diagnoses of cancer on EUS biopsy (n=17) – GIST (14), Schwanomma (1), Granular cell tumor (1), Adenocarcinoma (1).ConclusionsThis study confirms that EUS-FNA of submucosal lesions can be highly effective and safely carried out. Overall adequacy of tissue acquisition is in compliance with ESGE & JAG guidelines. Our diagnostic yield is in in keeping with the published literature.Abstract P317 Table 1EUS biopsy analysis EUS biopsy Analysis EUS biopsy including inadequate tissue sampling (n= 39) EUS biopsy excluding inadequate tissue sampling (n=33) Diagnostic accuracy 85% 100% Sensitivity 94.8% 100% Specificity 100% 100% Positive predictive value 100% 100% Negative predictive value 94.1% 100%
We currently cannot retrieve any items related to this title. Kindly check back at a later time.